Arima Genomics, a company at the forefront of leveraging whole-genome sequence and structure information to inform comprehensive cancer therapy selection, has made a significant announcement: the appointment of Tom Willis, PhD, as its new Chief Executive Officer and the simultaneous close of a substantial $22 million Series C financing round. This crucial funding, spearheaded by Illumina Ventures and bolstered by contributions from genomics pioneers John Stuelpnagel and Mostafa Ronaghi, PhD, alongside existing investors Co-Win Ventures and Berkeley Catalyst Fund, marks a pivotal strategic shift as Arima intensifies its commitment to revolutionizing oncology testing. Dr. Willis, bringing over two decades of robust company-building experience, including founding and leading successful ventures like ParAllele BioScience and Sequenta—whose ClonoSEQ® assay became a National Comprehensive Cancer Network (NCCN)-endorsed standard—expressed his confidence in Arima’s unique proprietary platform. This platform stands out by capturing how DNA is organized inside the nucleus, uniquely uniting chromatin architecture with sequence data in a single readout, allowing it to illuminate crucial genomic aspects often overlooked by other tests, such as gene fusions and rearrangements that are vital for diagnosis, prognosis, and therapy selection across numerous cancers, already benefiting patients through the company's CLIA-certified Aventa clinical testing laboratory. Under Willis's leadership, and with founder Sid Selvaraj, PhD, transitioning to President and Chief Operating Officer, Arima is poised to build upon its decade of discovery-driven research to launch a focused pipeline of clinical assays, aiming to establish a definitive diagnostic platform that can capture the genomic drivers of cancer at every scale and deliver actionable answers, ultimately striving to transform cancer into a more manageable disease.